Effects of the adenosine A(1) receptor agonist N(6)-cyclopentyladenosine on phencyclidine-induced behavior and expression of the immediate-early genes in the discrete brain regions of rats.
Leo Gotoh, Noriko Kawanami, Tatsuo Nakahara, Hisao Hondo, Keisuke Motomura, Eiko Ohta, Izumi Kanchiku, Toshihide Kuroki, Makoto Hirano, Hideyuki Uchimura
Brain research. Molecular brain research April 30, 2002 DOI: 10.1016/s0169-328x(02)00136-5 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical animal study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | N(6)-cyclopentyladenosine (CPA) phencyclidine (PCP) |
| Dose | CPA 0.5 mg/kg, s.c.; PCP 7.5 mg/kg, s.c. |
| Measures | locomotor activity, head weaving, mRNA levels of arc, c-fos, and jun B |
| Key points | The selective adenosine A(1) receptor agonist CPA (0.5 mg/kg) significantly attenuated PCP-induced hyperlocomotion and head weaving, and reduced PCP-induced increases in c-fos mRNA in the medial prefrontal cortex and nucleus accumbens and arc expression in the medial prefrontal cortex and posterior cingulate cortex. The authors conclude these results provide further evidence for a significant antipsychotic effect of adenosine A(1) receptor agonists. |
Abstract
Because of the possible interaction between adenosine receptors and dopaminergic functions, the compound acting on the specific adenosine receptor subtype may be a candidate for novel antipsychotic drugs. To elucidate the antipsychotic potential of the selective adenosine A(1) receptor agonist N(6)-cyclopentyladenosine (CPA), we examined herein the effects of CPA on phencyclidine (PCP)-induced behavior and expression of the immediate-early genes (IEGs), arc, c-fos and jun B, in the discrete brain regions of rats. PCP (7.5 mg/kg, s.c.) increased locomotor activity and head weaving in rats and this effect was significantly attenuated by pretreatment with CPA (0.5 mg/kg, s.c.). PCP increased the mRNA levels of c-fos and jun B in the medial prefrontal cortex, nucleus accumbens and posterior cingulate cortex, while leaving the striatum and hippocampus unaffected. CPA pretreatment significantly attenuated the PCP-induced increase in c-fos mRNA levels in the medial prefrontal cortex and nucleus accumbens. CPA also significantly attenuated the PCP-induced arc expression in the medial prefrontal cortex and posterior cingulate cortex. When administered alone, CPA decreased the mRNA levels of all IEGs examined in the nucleus accumbens, but not in other brain regions. Based on the ability of CPA to inhibit PCP-induced hyperlocomotion and its interaction with neural systems in the medial prefrontal cortex, posterior cingulate cortex and nucleus accumbens, the present results provide further evidence for a significant antipsychotic effect of the adenosine A(1) receptor agonist.
Citations in the library
Cited by 2
- Positive association of phencyclidine-responsive genes, PDE4A and PLAT, with schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics December 2011
- Activation of adenosine(1) (A(1)) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats. Neuropharmacology March 24, 2009
Cites 8
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats Science August 28, 1998
- Development of tolerance and supersensitivity to phencyclidine in rats after repeated administration of phencyclidine. European Journal of Pharmacology March 3, 1987
- M100907, a selective 5-HT(2A) receptor antagonist, attenuates phencyclidine-induced Fos expression in discrete regions of rat brain. European Journal of Pharmacology April 13, 2001
- Characterization of MK-801-induced behavior as a putative rat model of psychosis. Journal of Pharmacology and Experimental Therapeutics September 1, 1999
and 3 more in the library